Evidence map›Paper›PMID 31227502›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

When Cancer Vaccines Go Viral.

David Repáraz, Diana Llopiz, Pablo Sarobe

Abstract readComment
PubMed Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

David RepárazCentro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.ORCID 0000-0003-2706-6870
Diana LlopizCentro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Pablo SarobeCentro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain. psarobe@unav.es.
Navarre Institute of Health Research · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Induction of antitumor responses by vaccines requires strong immunogens. Heterologous viral prime/boost immunization with the BN-CV301 vaccine promotes activation of immune responses that provide a clinical benefit to patients with cancer. This viral platform may be used to harbor different antigens and prime tumor immunity potentially useful for combinatorial strategies.

Indexed as

Cancer VaccinesVaccines, DNAHumansVaccinationCancer VaccinesVaccines, DNA

Identifiers

PMID31227502
OpenAlexW2950087335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.